GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise 
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
Airbus Joins Air India A320 Altitude Drop Probe 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks 
US Plans Kenya Ebola Quarantine Facility Amid Congo Outbreak 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
On Tuesday, Pfizer announced its decision to donate the rights of royalties from sales of the cancer drug Bavencio to the American Association for Cancer Research. This move comes as a response to concerns raised by US antitrust regulators regarding Pfizer's proposed $43 billion acquisition of Seagen.
After receiving all necessary regulatory approvals, the deal is set to close on Thursday, nearly nine months since its initial announcement, as per Reuters.
Reorganization and Leadership Changes
Pfizer plans to establish a separate division dedicated to cancer drugs as part of its efforts to streamline operations. Additionally, the company intends to split its remaining commercial business into two divisions, one focused on the United States and the other on the rest of the world.
Chief Commercial Officer Angela Hwang will step down, allowing Aamir Malik to assume the US unit's commercial chief role. In the international unit, Alexandre de Germay will take on the position of commercial chief.
Sales and Financial Outlook
Bavencio, a vital cancer drug, generated sales amounting to $271 million for Pfizer in 2022. This acquisition of Seagen, with its targeted cancer therapies, comes at a crucial time for Pfizer. Facing the anticipated decline in COVID-related sales and the looming threat of generic competition for its top-selling drugs, Pfizer seeks to bolster its oncology portfolio and maintain its position as a leader in the pharmaceutical industry.
However, the acquisition faced scrutiny from the US Federal Trade Commission (FTC) earlier this year. In July, the FTC requested more information on the deal from both parties involved, seeking to ensure compliance with antitrust laws. Despite this additional hurdle, Pfizer remains committed to moving forward with the acquisition and closing the deal as planned.
Business Times noted that Seagen, based in Washington, is recognized as a pioneer of antibody-drug conjugates. These innovative treatments function like "guided missiles," specifically designed to target and destroy cancer cells while sparing healthy cells. With this cutting-edge technology and expertise, Seagen contributes to advancing more effective and targeted cancer therapies.
Photo: Pfizer Newsroom
